Leukemia & Lymphoma最新文献_第8页

Challenges of treating mantle cell lymphoma in older adults. 老年人套细胞淋巴瘤治疗的挑战。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI: 10.1080/10428194.2024.2431563

Javier Muñoz, Mazie Tsang, Yucai Wang, Tycel Phillips

引用次数: 0

Follow-up in patients with lymphoma: a call for an evidence-based approach. 淋巴瘤患者的随访：呼吁采取循证方法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-15 DOI: 10.1080/10428194.2024.2426053

Marc Sorigue

引用次数: 0

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. 在IMerge三期研究中，对于不符合使用促红细胞生成药物条件或复发/难治且输血负担较重的低风险骨髓增生异常综合征患者，依美司他能持续改善患者报告的疲劳症状。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-13 DOI: 10.1080/10428194.2024.2426057

Mikkael A Sekeres, Valeria Santini, Maria Díez-Campelo, Rami S Komrokji, Pierre Fenaux, Michael R Savona, Yazan F Madanat, David Valcárcel-Ferreiras, Esther Natalie Oliva, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Amer M Zeidan, Uwe Platzbecker

引用次数: 0

CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia. CDKN2A/B缺失作为儿童B细胞前体急性淋巴细胞白血病异基因造血干细胞移植的独立负面预后因素

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-01 DOI: 10.1080/10428194.2024.2434177

Anna Paisiou, Christina OIkonomopoulou, Dimitris Pavlidis, Mirella Ampatzidou, Anna Komitopoulou, Eleni-Dikaia Ioannidou, Aikaterini Kaisari, Georgia Avgeriou, Nikolaos Katzilakis, Eleni Dana, Marianna Tzanoudaki, Michalis Kastamoulas, Georgia Stavroulaki, Eugenia Papakonstantinou, Emmanouil Hatzipantelis, Athanasios Tragiannidis, Dimitrios Doganis, Sophia Polychronopoulou, Stefanos Ioannis Papadhimitriou, Evgenios Goussetis

引用次数: 0

Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management. SAPS 3用于预测需要ICU管理的血液恶性肿瘤患者住院死亡率的验证

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-02 DOI: 10.1080/10428194.2024.2423251

Sebastián Gil-Tamayo, Cándida Díaz-Brochero, Julio Solano, Óscar Contreras, Laura Arenas, Sandra García, Óscar M Muñoz-Velandia

{"title":"Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management.","authors":"Sebastián Gil-Tamayo, Cándida Díaz-Brochero, Julio Solano, Óscar Contreras, Laura Arenas, Sandra García, Óscar M Muñoz-Velandia","doi":"10.1080/10428194.2024.2423251","DOIUrl":"10.1080/10428194.2024.2423251","url":null,"abstract":"Prognostic systems predicting death risk may vary for patients with haematological malignancies needing ICU care. This study externally validated SAPS 3 using a retrospective cohort of adults with these conditions in the ICU. The score was calculated at admission using the general and South America-adjusted formulas. Mortality discrimination was assessed via AUC-ROC, and calibration by Hosmer-Lemeshow goodness-of-fit and graphical analysis with a calibration belt. The analysis included 273 admissions, with 119 deaths. Discriminative capacity was low (AUC-ROC 0.56, CI 95% 0.49-0.63). There was a poor correlation between expected and observed events across all risk deciles (Hosmer-Lemeshow 10.45, p = 0.0635). Similar results were found with the South America-adjusted formula. SAPS 3 does not effectively discriminate between survivors and non-survivors, underestimating risk in low-risk groups and overestimating it in high-risk groups. Mortality risk estimation in this scenario should rely on clinical judgment.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"451-457"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy. 细胞因子水平的变化与接受 R-CHOP 化疗的淋巴瘤患者与癌症相关的认知障碍有关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-15 DOI: 10.1080/10428194.2024.2424373

Pinki Mishra, Dinesh Bhurani, Mohd Ashif Khan, Nidhi

{"title":"Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy.","authors":"Pinki Mishra, Dinesh Bhurani, Mohd Ashif Khan, Nidhi","doi":"10.1080/10428194.2024.2424373","DOIUrl":"10.1080/10428194.2024.2424373","url":null,"abstract":"Cancer-related cognitive impairment (CRCI) is a significant issue commonly observed following chemotherapy treatment. The study aimed to investigate the changes in cognitive function and their association with IL-6, IL-1β, and IL-10 levels before and after R-CHOP chemotherapy over six cycles. Seventy chemotherapy naïve, newly diagnosed lymphoma patients were enrolled. Cognitive functions and inflammatory cytokines were assessed at baseline (TP1), after 3rd cycle (TP2), and after 6th cycle (TP3). Patients, with mean age of 44.17 ± 13.67 years, showed significantly increased levels of IL-6 and IL-1β and decreased IL-10 levels over time (p < .001). On the Montreal Cognitive Assessment (MoCA), scores of domains such as executive functioning (p = .002), attention (p < .001), language (p < .001), recall (p = .005), and orientation (p < .001) significantly decreased post six cycles of R-CHOP chemotherapy. Correlation analysis at TP2 indicated a positive association between elevated IL-6 levels with a decrease in MoCA scores indicating a decline in cognitive function (ρ = 0.68, p < .001). At TP3, no association of MoCA scores with IL-6 and IL-1β was observed. Decreased IL-10 levels showed a weak association with decreased MoCA scores at TP2 and TP3 (ρ = 0.2, p = .09; for TP3, ρ = 0.16, p = .17), but this was not significant. In summary, the findings of the present study highlight significant cognitive decline and changes in inflammatory cytokine levels following six cycles of R-CHOP. Objective cognitive assessments may be done to detect CRCI in patients treated with R-CHOP.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"516-528"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement. FISH与RT-PCR相结合，通过更好地识别ZNF384重排，有助于对中国成年B型其他ALL患者进行分类。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-09 DOI: 10.1080/10428194.2024.2426055

Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang

{"title":"FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.","authors":"Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang","doi":"10.1080/10428194.2024.2426055","DOIUrl":"10.1080/10428194.2024.2426055","url":null,"abstract":"ZNF384 gene rearrangements are a distinct subtype of adult B cell acute lymphoblastic leukemia (B-ALL). We screened 46 B-other ALL patients for ZNF384 fusions using fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR). Clinical data, treatment response, and minimal residual disease (MRD) status were analyzed. Ten (21.7%) patients were ZNF384-r positive (nine by FISH, nine by RT-PCR, eight by both). FISH showed atypical signals, including 3' signal gain and 5' signal deletion. EP300 was the main fusion partner (n = 5). TAF15::ZNF384, SYNRG::ZNF384, CREBBP::ZNF384, and TCF3::ZNF384 fusions were found in one patient each; one case's partner gene is unknown. One patient was MRD-negative at the end of the first induction, lower than in patients without ZNF384-r. ZNF384-r incidence matched B-other ALL incidence in Chinese patients. Combined FISH and RT-PCR improved detection. ALL with ZNF384-r has unique features, and lower MRD-negative response may indicate a negative impact on traditional treatments.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"507-515"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sweet syndrome with multiorgan involvement exacerbated by gilteritinib. 吉特替尼加剧了多器官受累的斯威特综合征。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-14 DOI: 10.1080/10428194.2024.2426061

Ana Jiménez-Sánchez, María Olivares-Guerrero, Mario Aparicio-Domínguez, Sonsoles Berenguer-Ruiz, Luis Miguel Juárez-Salcedo, Patricia Muñoz-Hernández, Fernando Gallardo, Beatriz Bellosillo, Mar Llamas-Velasco

引用次数: 0

Infections during novel myeloma therapies. 新型骨髓瘤疗法期间的感染。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-18 DOI: 10.1080/10428194.2024.2428819

Alice J Liu, Monica A Slavin, Simon J Harrison, Benjamin W Teh

引用次数: 0

Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-27 DOI: 10.1080/10428194.2025.2470784

Michelle Tan, Masa Lasica, Vanessa Donati, Kirsty Rady, Meena Nagarethinam, Shaun Fleming, Anthony Schwarer, Andrew Grigg, Stephen B Ting

{"title":"Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.","authors":"Michelle Tan, Masa Lasica, Vanessa Donati, Kirsty Rady, Meena Nagarethinam, Shaun Fleming, Anthony Schwarer, Andrew Grigg, Stephen B Ting","doi":"10.1080/10428194.2025.2470784","DOIUrl":"https://doi.org/10.1080/10428194.2025.2470784","url":null,"abstract":"Paediatric-inspired acute lymphoblastic leukaemia (ALL) regimens have led to improved leukaemic outcomes in adults. However, avascular necrosis (AVN) has emerged as a debilitating orthopaedic complication. AVN is likely multifactorial, with corticosteroids and asparaginase therapy playing key roles in its pathogenesis. We assessed the incidence and potential risk factors for AVN, in older adolescent and adult patients with ALL treated with the FRALLE-93 protocol across three Australian tertiary centres. AVN occurred in 24% of 59 patients, primarily affecting hip and knee joints. Diagnosis occurred at a median of 11.7 months from commencement of chemotherapy. No association was identified between AVN risk and sex, age, BMI, smoking status and vitamin D level. The majority of patients required orthopaedic intervention (64%). Approximately two thirds had chronic pain or impaired mobility. AVN risk in adult patients with ALL receiving FRALLE protocols appears at least comparable to rates reported in paediatric cohorts.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0